Tao Jifang, Wu Hao, Coronado Amanda A, de Laittre Elizabeth, Osterweil Emily K, Zhang Yi, Bear Mark F
Picower Institute for Learning and Memory and.
Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139.
J Neurosci. 2016 Nov 23;36(47):11946-11958. doi: 10.1523/JNEUROSCI.0672-16.2016.
Rett syndrome (RTT) is caused by mutations in the gene encoding methyl-CpG binding protein 2 (MECP2), an epigenetic regulator of mRNA transcription. Here, we report a test of the hypothesis of shared pathophysiology of RTT and fragile X, another monogenic cause of autism and intellectual disability. In fragile X, the loss of the mRNA translational repressor FMRP leads to exaggerated protein synthesis downstream of metabotropic glutamate receptor 5 (mGluR5). We found that mGluR5- and protein-synthesis-dependent synaptic plasticity were similarly altered in area CA1 of Mecp2 KO mice. CA1 pyramidal cell-type-specific, genome-wide profiling of ribosome-bound mRNAs was performed in wild-type and Mecp2 KO hippocampal CA1 neurons to reveal the MeCP2-regulated "translatome." We found significant overlap between ribosome-bound transcripts overexpressed in the Mecp2 KO and FMRP mRNA targets. These tended to encode long genes that were functionally related to either cytoskeleton organization or the development of neuronal connectivity. In the Fmr1 KO mouse, chronic treatment with mGluR5-negative allosteric modulators (NAMs) has been shown to ameliorate many mutant phenotypes by correcting excessive protein synthesis. In Mecp2 KO mice, we found that mGluR5 NAM treatment significantly reduced the level of overexpressed ribosome-associated transcripts, particularly those that were also FMRP targets. Some Rett phenotypes were also ameliorated by treatment, most notably hippocampal cell size and lifespan. Together, these results suggest a potential mechanistic link between MeCP2-mediated transcription regulation and mGluR5/FMRP-mediated protein translation regulation through coregulation of a subset of genes relevant to synaptic functions.
Altered regulation of synaptic protein synthesis has been hypothesized to contribute to the pathophysiology that underlies multiple forms of intellectual disability and autism spectrum disorder. Here, we show in a mouse model of Rett syndrome (Mecp2 KO) that metabotropic glutamate receptor 5 (mGluR5)- and protein-synthesis-dependent synaptic plasticity are abnormal in the hippocampus. We found that a subset of ribosome-bound mRNAs was aberrantly upregulated in hippocampal CA1 neurons of Mecp2 KO mice, that these significantly overlapped with FMRP direct targets and/or SFARI human autism genes, and that chronic treatment of Mecp2 KO mice with an mGluR5-negative allosteric modulator tunes down upregulated ribosome-bound mRNAs and partially improves mutant mice phenotypes.
雷特综合征(RTT)由编码甲基CpG结合蛋白2(MECP2)的基因突变引起,MECP2是一种mRNA转录的表观遗传调节因子。在此,我们报告了一项关于RTT和脆性X综合征(另一种导致自闭症和智力残疾的单基因病因)共享病理生理学假说的测试。在脆性X综合征中,mRNA翻译抑制因子FMRP的缺失导致代谢型谷氨酸受体5(mGluR5)下游蛋白质合成过度。我们发现,在Mecp2基因敲除小鼠的CA1区中,mGluR5和蛋白质合成依赖性突触可塑性同样发生改变。在野生型和Mecp2基因敲除小鼠海马CA1神经元中进行了CA1锥体细胞类型特异性的全基因组核糖体结合mRNA分析,以揭示MeCP2调节的“翻译组”。我们发现,在Mecp2基因敲除小鼠中过表达的核糖体结合转录本与FMRP mRNA靶标之间存在显著重叠。这些转录本倾向于编码与细胞骨架组织或神经元连接发育功能相关的长基因。在Fmr1基因敲除小鼠中,已证明用mGluR5负变构调节剂(NAMs)进行慢性治疗可通过纠正过度蛋白质合成来改善许多突变表型。在Mecp2基因敲除小鼠中,我们发现mGluR5 NAM治疗显著降低了过表达的核糖体相关转录本的水平,尤其是那些也是FMRP靶标的转录本水平。一些雷特综合征表型也通过治疗得到改善,最显著的是海马细胞大小和寿命。总之,这些结果表明,通过对与突触功能相关的一组基因的共同调节,MeCP2介导的转录调节与mGluR5/FMRP介导的蛋白质翻译调节之间存在潜在的机制联系。
突触蛋白合成调节异常被认为与多种形式的智力残疾和自闭症谱系障碍的病理生理学有关。在此,我们在雷特综合征小鼠模型(Mecp2基因敲除)中表明,代谢型谷氨酸受体5(mGluR5)和蛋白质合成依赖性突触可塑性在海马中异常。我们发现,在Mecp2基因敲除小鼠的海马CA1神经元中,一部分核糖体结合mRNA异常上调,这些转录本与FMRP直接靶标和/或SFARI人类自闭症基因显著重叠,并且用mGluR5负变构调节剂对Mecp2基因敲除小鼠进行慢性治疗可下调上调的核糖体结合mRNA,并部分改善突变小鼠的表型。